TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-γ double knockout effector T cells

被引:56
作者
Poehlein, CH
Hu, HM
Yamada, J
Assmann, K
Alvord, WG
Urba, WJ
Fox, BA
机构
[1] Providence Portland Med Ctr, Earle A Chiles Res Inst, Robert W Franz Canc Res Ctr, Lab Mol & Tumor Immunol, Portland, OR 97213 USA
[2] Providence Portland Med Ctr, Earle A Chiles Res Inst, Robert W Franz Canc Res Ctr, Lab Clin Res, Portland, OR 97213 USA
[3] Oregon Hlth & Sci Univ, Oregon Grad Inst, Dept Biochem & Mol Biol, Portland, OR 97202 USA
[4] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97202 USA
[5] Oregon Hlth & Sci Univ, Oregon Canc Ctr, Portland, OR 97202 USA
[6] NCI, Frederick Canc Res & Dev Ctr, Data Management Serv, Frederick, MD 21702 USA
关键词
D O I
10.4049/jimmunol.170.4.2004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have recently shown that effector T cells (T-E) lacking either perforin or IFN-gamma are highly effective mediators of tumor regression. To rule out compensation by either mechanism, TE deficient in both perforin and IFN-gamma (perforin knockout (PKO)/IFN-gamma knockout (GKO)) were generated. The adoptive transfer of PKO/GKO T, mediated complete tumor regression and cured wild-type animals with established pulmonary metastases of the B16BL6-D5 (D5) melanoma cell line. PKO/GKO T-E also mediated tumor regression in D5 tumor-bearing PKO, GKO, or PKO/GKO recipients, although in PKO/GKO recipients efficacy was reduced. PKO/GKO T-E exhibited tumor-specific TNF-alpha production and cytotoxicity in a 24-h assay, which was blocked by the soluble TNFRII-human IgG fusion protein (TNFRII:Fc). Blocking TNF in vivo by administering soluble TNFR 11 fusion protein (TNFRII:Fc) significantly reduced the therapeutic efficacy of PKO/GKO, but not wild-type T-E. This study identifies perforin, IFN-gamma and TNF as a critical triad of effector molecules that characterize therapeutic antitumor T cells. These insights could be used to monitor and potentially tune the immune response to cancer vaccines.
引用
收藏
页码:2004 / 2013
页数:10
相关论文
共 55 条
[11]   Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2 [J].
Chang, AE ;
Aruga, A ;
Cameron, MJ ;
Sondak, VK ;
Normolle, DP ;
Fox, BA ;
Shu, SY .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :796-807
[12]  
CHANG AE, 1986, CANCER RES, V46, P3426
[13]  
CHAUVENET PH, 1979, J IMMUNOL, V123, P2575
[14]  
CHEEVER MA, 1981, CANCER RES, V41, P2658
[15]   PROTECTION AGAINST SYNGENEIC LYMPHOMA BY A LONG-LIVED CYTO-TOXIC T-CELL CLONE [J].
DAILEY, MO ;
PILLEMER, E ;
WEISSMAN, IL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (17) :5384-5387
[16]   Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection [J].
Dobrzanski, MJ ;
Reome, JB ;
Dutton, RW .
JOURNAL OF IMMUNOLOGY, 2001, 167 (01) :424-434
[17]  
Fallarino F, 1999, J IMMUNOL, V163, P4109
[18]  
FERNANDEZCRUZ E, 1979, J IMMUNOL, V123, P1772
[19]  
FOX BA, 1990, J BIOL RESP MODIF, V9, P499
[20]   CLONING AND EXPRESSION OF CDNA FOR HUMAN LYMPHOTOXIN, A LYMPHOKINE WITH TUMOR NECROSIS ACTIVITY [J].
GRAY, PW ;
AGGARWAL, BB ;
BENTON, CV ;
BRINGMAN, TS ;
HENZEL, WJ ;
JARRETT, JA ;
LEUNG, DW ;
MOFFAT, B ;
NG, P ;
SVEDERSKY, LP ;
PALLADINO, MA ;
NEDWIN, GE .
NATURE, 1984, 312 (5996) :721-724